Latest News Releases Keyword Search Year All2026202520242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996 5/6/26 Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia 5/5/26 Neurocrine Biosciences Reports First-Quarter 2026 Financial Results 5/5/26 Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 5/4/26 Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment 5/4/26 Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist 5/1/26 Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia Resources Email Alerts 2025 Annual Report 2026 Proxy Statement Webcasts & Presentations
5/6/26 Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
5/4/26 Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
5/4/26 Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
5/1/26 Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia